Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to investigate whether the addition of 3 additional
neo-adjuvant cycles of chemotherapy (doxorubicin and ifosfamide) to standard management
according to the ISG-STS 10-01 study (3 cycles of neoadjuvant doxorubicin and ifosfamide
based chemotherapy + surgery +/- radiotherapy) improves the outcome of high-risk CINSARC
patients with resectable soft-tissue sarcoma (STS). Primary endpoint is metastatic
progression-free survival (M-PFS, after 3 years of follow-up).